Ginkgo Bioworks Holdings (DNA) Tax Provisions (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Tax Provisions came in at -$80000.0 in Q1 2026, down 190.91% YoY from $88000.0 in Q1 2025, and up 87.56% on a QoQ basis from -$643000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Tax Provisions (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Tax Provisions data on file, last reported at -$80000.0 in Q1 2026.
- Quarterly Tax Provisions fell 190.91% year-over-year to -$80000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 138.15% YoY) and the FY2025 annual result came in at -$837000.0, down 74.74% from the prior year.
- Tax Provisions grew to -$80000.0 in Q1 2026, from -$643000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $190000.0 in Q2 2024 to a low of -$14.8 million in Q4 2022.
- A 5-year average of -$970235.3 and a median of -$45000.0 in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions tumbled 2062.52% — and 2023, when it soared 248.89%.
- Tracing DNA's Tax Provisions over 5 years: stood at -$14.8 million in 2022, then surged by 98.66% to -$198000.0 in 2023, then tumbled by 64.14% to -$325000.0 in 2024, then slumped by 97.85% to -$643000.0 in 2025, then surged by 87.56% to -$80000.0 in 2026.
- The last three Tax Provisions figures came in at -$80000.0 (Q1 2026), -$643000.0 (Q4 2025), and $1000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 128,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128,000.00 |
| Mar 31, 2026 | -80,000.00 |
| Dec 31, 2025 | -643,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | -283,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | -325,000.00 |
| Sep 30, 2024 | -375,000.00 |
| Jun 30, 2024 | 190,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Sep 30, 2023 | -22,000.00 |
| Jun 30, 2023 | 67,000.00 |
| Mar 31, 2023 | 82,000.00 |
| Dec 31, 2022 | -14.77 Mn |
| Sep 30, 2022 | -28,000.00 |
| Jun 30, 2022 | -45,000.00 |
| Mar 31, 2022 | -184,000.00 |
| Dec 31, 2021 | -683,000.00 |
| Sep 30, 2021 | -207,000.00 |